Profile data is unavailable for this security.
About the company
Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology (IO) targets including human epidermal growth factor (EGF) receptor 2 (HER2), human EGF receptor 3 (HER3) and programmed cell death protein (PD-1). The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates (ADCs) and others.
- Revenue in USD (TTM)0.00
- Net income in USD-8.88m
- Incorporated2019
- Employees2.00
- LocationTharimmune Inc1200 Route 22 EastBRIDGEWATER 08807United StatesUSA
- Phone+1 (302) 743-2995
- Fax+1 (302) 645-1280
- Websitehttps://tharimmune.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Templates Inc | 25.47m | -15.63m | 2.36m | 62.00 | -- | 0.3314 | -- | 0.0925 | -2.70 | -2.70 | 4.24 | 1.08 | 0.8189 | -- | 47.65 | 410,806.40 | -50.24 | -51.78 | -113.26 | -73.14 | -- | -- | -61.35 | -228.33 | -- | -- | 0.00 | -- | 190.10 | 33.96 | 91.24 | -- | -48.87 | -- |
| Phio Pharmaceuticals Corp | 0.00 | -8.68m | 2.54m | 8.00 | -- | 0.3989 | -- | -- | -23.77 | -23.77 | 0.00 | 7.40 | 0.00 | -- | -- | 0.00 | -98.62 | -71.92 | -126.86 | -84.15 | -- | -- | -- | -253,785.70 | -- | -- | 0.00 | -- | -- | -- | 5.70 | -- | 0.00 | -- |
| Halberd Corp | 281.24k | 25.34k | 2.54m | 3.00 | 1.72 | -- | 100.26 | 9.04 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
| GRI Bio Inc | 0.00 | -8.28m | 2.56m | 4.00 | -- | 0.1487 | -- | -- | -100.69 | -100.69 | 0.00 | 5.88 | 0.00 | -- | -- | 0.00 | -130.64 | -192.93 | -187.01 | -353.99 | -- | -- | -- | -37,650.49 | -- | -- | 0.00 | -- | -- | -- | -85.61 | -- | 29.46 | -- |
| Protagenic Therapeutics Inc | 0.00 | -6.40m | 2.68m | 1.00 | -- | 3.38 | -- | -- | -1.45 | -1.45 | 0.00 | 0.1774 | 0.00 | -- | -- | 0.00 | -152.72 | -74.49 | -206.36 | -92.56 | -- | -- | -- | -- | -- | -17.09 | 0.00 | -- | -- | -- | -40.64 | -- | -- | -- |
| Tharimmune Inc | 0.00 | -8.88m | 2.72m | 2.00 | -- | 0.3877 | -- | -- | -55.46 | -55.46 | 0.00 | 6.11 | 0.00 | -- | -- | 0.00 | -138.06 | -- | -181.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.98 | -- | -- | -- |
| Biostax Corp | 0.00 | -1.51m | 2.81m | -- | -- | -- | -- | -- | -0.0181 | -0.0181 | 0.00 | -0.0633 | 0.00 | -- | -- | -- | -395.44 | -81.51 | -- | -- | -- | -- | -- | -- | -- | -4.04 | -- | -- | -- | -- | 53.32 | -- | -- | -- |
| Bone Biologics Corp | 0.00 | -5.12m | 2.85m | 2.00 | -- | 0.615 | -- | -- | -10.26 | -10.26 | 0.00 | 2.21 | 0.00 | -- | -- | 0.00 | -94.66 | -98.31 | -119.03 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -502.76 | -- | -- | -- |
| Galera Therapeutics Inc | 0.00 | -29.11m | 2.88m | 7.00 | -- | -- | -- | -- | -0.5892 | -0.5892 | 0.00 | -2.54 | 0.00 | -- | -- | 0.00 | -90.03 | -83.69 | -119.01 | -97.54 | -- | -- | -- | -- | -- | -14.34 | 11.60 | -- | -- | -- | 5.05 | -- | -29.84 | -- |
| Gritstone bio Inc | 14.61m | -133.03m | 2.95m | 231.00 | -- | 0.1327 | -- | 0.2021 | -1.35 | -1.35 | 0.1391 | 0.1884 | 0.08 | -- | 49.20 | 63,251.08 | -72.86 | -48.08 | -83.37 | -55.18 | -- | -- | -910.50 | -573.71 | -- | -97.11 | 0.6461 | -- | -18.05 | 68.96 | -15.71 | -- | -4.19 | -- |
| Palisade Bio Inc | 0.00 | -14.17m | 3.01m | 9.00 | -- | 0.2465 | -- | -- | -20.07 | -20.07 | 0.00 | 10.30 | 0.00 | -- | -- | 0.00 | -90.97 | -132.36 | -109.07 | -165.45 | -- | -- | -- | -27,892.32 | -- | -972.73 | 0.0339 | -- | -- | -0.7814 | 13.74 | -- | 18.53 | -- |
| Revelation Biosciences Inc | 0.00 | -15.90m | 3.08m | 9.00 | -- | 1.18 | -- | -- | -29.75 | -29.75 | 0.00 | 0.6939 | 0.00 | -- | -- | 0.00 | -112.35 | -- | -253.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 98.89 | -- | -- | -- |
| Aditxt Inc | 329.75k | -43.31m | 3.12m | 47.00 | -- | 0.0027 | -- | 9.47 | -3,088.09 | -3,088.09 | 12.12 | 131.74 | 0.0185 | 0.6082 | 0.8393 | 7,015.96 | -242.33 | -192.78 | -1,548.63 | -321.59 | -46.09 | -- | -13,105.77 | -7,208.65 | 0.0458 | -3.53 | 0.5084 | -- | -30.90 | -- | -18.11 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Curi RMB Capital LLCas of 30 Sep 2024 | 23.62k | 2.06% |
| UBS Securities LLCas of 30 Jun 2024 | 5.17k | 0.45% |
| Tower Research Capital LLCas of 30 Jun 2024 | 1.00k | 0.09% |
| Bank of America, NA (Private Banking)as of 30 Jun 2024 | 6.00 | 0.00% |
| JPMorgan Securities LLC (Investment Management)as of 30 Sep 2024 | 1.00 | 0.00% |
| XTX Markets LLCas of 30 Jun 2024 | 0.00 | 0.00% |
| Wells Fargo Bank, NA (Private Banking)as of 30 Jun 2024 | 0.00 | 0.00% |
| Two Sigma Investments LPas of 30 Jun 2024 | 0.00 | 0.00% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 0.00 | 0.00% |
| Two Sigma Advisers LPas of 30 Jun 2024 | 0.00 | 0.00% |
